Platelet lysate promotes re-epithelialization of persistent epithelial defects: a pilot study

Abu‐Ameerh, Mohammed; Jafar, Hanan; Hasan, Maram; Bdour, Muawyah; Msallam, Mohammed M.; Ababneh, Osama H.; Alhattab, Dana; Al-Kurdi, Ban; Awidi, Abdelhalim; Awidi, Abdalla

doi:10.1007/s10792-018-0968-1

Cited by 13 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a human clinical study, Geremicca et al (2010) found that PL is an effective substance to treat patients with corneal lesions. Another study by Abu-Ameerh et al (2018) on patients with persistent corneal epithelial defects found that PL improved symptoms and promoted re-epithelialization. Another study by Fea and Aragno (2016) revealed that the use of PL eye drops was effective in treating patients with early Sjogren syndrome.…”

Section: Ocular Diseasementioning

confidence: 97%

Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use?

Zamani

Yaghoubi

Movassaghpour

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Hemoderivative materials are used to treat different diseases. These derivatives include platelet‐rich plasma, serum, platelet gel, and platelet lysate (PL). Among them, PL contains more growth factors than the others and its production is inexpensive and easy. PL is one of the proper sources of platelet release factors. It is used in cells growth and proliferation and is a good alternative to fetal bovine serum. In recent years, the clinical use of PL has gained more appeal by scientists. PL is a solution saturated by growth factors, proteins, cytokines, and chemokines and is administered to treat different diseases such as wound healing, bone regeneration, alopecia, oral mucositis, radicular pain, osteoarthritis, and ocular diseases. In addition, it can be used in cell culture for cell therapy and tissue transplantation purposes. Platelet‐derived growth factor, fibroblast growth factor, insulin‐like growth factor, transforming growth factor β, and vascular endothelial growth factor are key PL growth factors playing a major role in cell proliferation, wound healing, and angiogenesis. In this paper, we scrutinized recent advances in using PL and PL‐derived growth factors to treat diseases and in regenerative medicine, and the ability to replace PL with other hemoderivative materials.

show abstract

Section: Ocular Diseasementioning

confidence: 97%

Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use?

Zamani

Yaghoubi

Movassaghpour

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Platelet lysate (PL) was prepared as previously described [19,20,21]. Breifly, platelet rich plasma (PRP) was obtained from 20 ml of autologous whole blood collected in citrated tubes and 5ml of platelet lysate was prepared subsequently.…”

Section: Platelet Lysatementioning

confidence: 99%

Platelet lysate promotes the healing of long-standing diabetic foot ulcers: A report of two cases and in vitro study

Jafar

Hasan

Alhattab

et al. 2020

Heliyon

View full text Add to dashboard Cite

Long-standing foot ulcers present a great challenge in diabetes care. Platelet products have been suggested as a possible therapeutic option. However, nor the effect of an injectable form of platelet lysate on the healing of ulcers nor that on primary cells of the epidermis have been studied. In the current study, we present two cases of an ongoing clinical trial showing the positive effect of autologous platelet lysate injected perilesional. Both clinical cases treated with injections of hPL showed complete healing of previously un-healed within 8 weeks of treatment. Further, we describe the in vitro effect of human platelet lysate (hPL) on primary human epidermal keratinocytes (HEK) in terms of chemotaxis, migration and proliferation. In vitro, HEK showed enhanced chemotaxis towards the hPL compared to keratinocyte-defined media (p < 0.0001). Their migration was also stimulated especially at hPL concentration of 10%V/V (p < 0.0001). In contrast, hPL significantly inhibited HEK proliferation measured through MTT assay (p < 0.0001). In conclusion, the findings presented here provide preliminary evidence of an explanatory mechanism for the effect of hPL on primary keratinocytes and therefore of their potential use in a clinical setting. hPL promotes keratinocyte migration and therefore closure of foot ulcers.

show abstract

“…БоФРП также представляет собой аутологичную плазму, обогащенную тромбоцитами, полученную из собственной крови пациента, которая после активации хлоридом кальция высвобождает пул биологически активных белков [45]. Лизат тромбоцитов получают из БоТП, который разбавляют до конечной концентрации 30%, затем подвергают термическому шоку, чтобы вызвать лизис тромбоцитов и высвобождение БоФРП [48].…”

Section: обзоры литературыunclassified

“…Концентрации TGF-β1, TGF-β2, EGF, витамина А и фибронектина в обеих субстанциях не отличались. Тем не менее концентрации EGF в PRP были значительно выше, чем в АС, и выше скорость заживления [48]. S. López-Plandolit оценил эф- [49].…”

Section: обзоры литературыunclassified

Modern biotechnological treatment methods of persistent corneal epithelial defects

Труфанов¹,

Subbot²,

Shakhbazyan³

2020

Vestn. oftal'mol.

View full text Add to dashboard Cite

Данный обзор посвящен современным методам терапии персистирующих эпителиальных дефектов роговицы. Рассмотрены основные факторы, влияющие на развитие этой патологии, обсуждается влияние лимбальной недостаточности как одного из наиболее вероятных факторов развития. Описаны наиболее перспективные методы лечения, а именно применение различных дериватов крови и клеточной терапии. Ключевые слова: персистирующий эпителиальный дефект роговицы, лимбальная недостаточность, аутологичная сыворотка, богатая тромбоцитами плазма, клеточная терапия.

show abstract

Platelet lysate promotes re-epithelialization of persistent epithelial defects: a pilot study

Abstract: Undiluted autologous platelet lysate, prepared according to a standardized methodology, is a safe and effective adjunct therapy for the treatment of PED.

Cited by 13 publications

References 23 publications

Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use?

Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use?

Platelet lysate promotes the healing of long-standing diabetic foot ulcers: A report of two cases and in vitro study

Modern biotechnological treatment methods of persistent corneal epithelial defects

Contact Info

Product

Resources

About